[1] Tiwari J. Navigating through orphan medicinal product regulations in EU and US-Similarities and differences[J]. Regul Toxicol Pharmacol, 2015, 71(1):63-67.
[2] Phillips M. I. & Burns A. B. The emergence of gene therapy for rare diseases[J]. Expert Opinion on Orphan Drugs, 2014, 2(11):1197-1209.
[3] Tambuyzer E. Rare diseases, orphan drugs and their regulation:Ques-tions and misconceptions[J]. Nature Reviews Drug Discovery, 2010, 9(12):921-929.
[4] Dye D E, Brameld K J, Maxwell S, et al. The impact of single gene and chromosomal disorders on hospital admissions of children and adoles-cents:A population-based study[J]. Public Health Genomics, 2011, 14(3):153-161.
[5] Mccandless S E, Brunger J W, Cassidy S B. The burden of genetic dis-ease on inpatient care in a children's hospital[J]. American Journal of Human Genetics, 2004, 74(1):121-127.
[6] Yoon P W, Olney R S, Khoury M J, et al. Contribution of birth defects and genetic diseases to pediatric hospitalizations. A population-based study[J]. Archives of Pediatrics & Adolescent Medicine, 1997, 151(11):1096-1103.
[7] Mckusick V A. Mendelian inheritance in man and its online version, OMIM[J]. American Journal of Human Genetics, 2007, 80(4):588-604.
[8] Cooper D N, Chen J M, Ball E V, et al. Genes, mutations, and human inherited disease at the dawn of the age of personalized genomics[J]. Human Mutation, 2010, 31(6):631-655.
[9] Cideciyan A V. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy[J]. Progress in Retinal & Eye Re-search, 2010, 29(5):398-427.
[10] Bacchetta R, Aiuti A, Seger R, et al. Gene therapy for primary immu-nodeficiencies:Part 2[J]. Current Opinion in Immunology, 2012, 24(5):585-591.
[11] Nathwani A C, Tuddenham E G, Rangarajan S, et al. Adenovirus-asso-ciated virus vector-mediated gene transfer in hemophilia B[J]. New England Journal of Medicine, 2011, 365(25):2357-2365.
[12] Manno C S, Pierce G F, Arruda V R, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response[J]. Nature Medicine, 2006, 12(3):342-347.
[13] Stroes E S, Nierman M C, Meulenberg J J, et al. Intramuscular admin-istration of AAV1-lipoprotein lipase S447X lowers triglycerides in li-poprotein lipase-deficient patients[J]. Arteriosclerosis Thrombosis & Vascular Biology, 2008, 28(12):2303-2304.
[14] Witmer C, Young G. Factor VⅢ inhibitors in hemophilia A:Rationale and latest evidence.[J]. Therapeutic Advances in Hematology, 2013, 4(1):59-72.
[15] Collins P W, Chalmers E, Hart D P, et al. Diagnosis and treatment of factor VⅢ and IX inhibitors in congenital haemophilia:(4th edition). UK Haemophilia Centre Doctors Organization[J]. British Journal of Haematology, 2013, 160(2):153-170.
[16] Büning H, Perabo L, Coutelle O, et al. Recent developments in adenoassociated virus vector technology[J]. Journal of Gene Medicine, 2008, 10(7):717-733.
[17] Nathwani A C, Reiss U M, Tuddenham E G D, et al. Long-term safe-ty and efficacy of factor IX gene therapy in hemophilia B[J]. New Eng-land Journal of Medicine, 2014, 371(21):1994-2004.
[18] Kattenhorn L M, Tipper C H, Stoica L, et al. Adeno-associated virus gene therapy for liver disease[J]. Human Gene Therapy, 2016, 27(12):947-961.
[19] Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readminis-tration in three adults with congenital blindness[J]. Science Transla-tional Medicine, 2012, 4(120):120ra15.
[20] Ashtari M, Zhang H, Cook P A, et al. Plasticity of the human visual system after retinal gene therapy in patients with Leber's congenital amaurosis.[J]. Science Translational Medicine, 2015, 7(296):296ra110.
[21] Jacobson S G, Cideciyan A V, Roman A J, et al. Improvement and de-cline in vision with gene therapy in childhood blindness.[J]. New Eng-land Journal of Medicine, 2015, 372(20):1920-1926.
[22] Bainbridge J W B, Mehat M S, Sundaram V, et al. Long-term effect of gene therapy on leber's congenital amaurosis[J]. New England Journal of Medicine, 2015, 372(20):1887-1997.
[23] Edwards T L, Jolly J K, Groppe M, et al. Visual Acuity after Retinal Gene Therapy for Choroideremia.[J]. New England Journal of Medi-cine, 2016, 374(20):1996-1998.
[24] Rabinowitz J E. Phase 1 gene therapy for Duchenne muscular dystro-phy using a translational optimized AAV vector[J]. Molecular Therapy the Journal of the American Society of Gene Therapy, 2012, 20(2):443-455.
[25] Fairclough R J, Wood M J, Davies K E. Therapy for Duchenne muscu-lar dystrophy:Renewed optimism from genetic approaches.[J]. Nature Reviews Genetics, 2013, 14(6):373-378.
[26] Long C, Amoasii L, Mireault A A, et al. Postnatal genome editing par-tially restores dystrophin expression in a mouse model of muscular dystrophy[J]. Science, 2016, 351(6271):400-403.
[27] Nelson C E, Hakim C H, Ousterout D G, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy[J]. Science, 2016, 351(6271):403-407.
[28] Tabebordbar M, Zhu K, Cheng J K W, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells[J]. Science, 2016, 351(6271):407-411.
[29] Long C Z, McAnally J R, Shelton J M, et al. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA[J]. Science, 2014, 345(6201):1184-1188.
[30] Hocquemiller M, Giersch L, Audrain M, et al. Adeno-associated virusbased gene therapy for CNS disease[J]. Human Gene Therapy, 2016, 27(7):478-496.
[31] Leone P, Shera D, Mcphee S W, et al. Long-term follow-up after gene therapy for canavan disease[J]. Science Translational Medicine, 2012, 4(165):165ra163.
[32] Cavazzana-Calvo M. Gene therapy of human severe combined immuno-deficiency (SCID)-X1 disease[J]. Science, 2000, 288(5466):669-672.
[33] Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning[J]. Sci-ence, 2002, 296(5577):2410-2413.
[34] Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodefi-ciency due to adenosine deaminase deficiency[J]. New England Jour-nal of Medicine, 2009, 360(5):447-458.
[35] Cartier N, Aubourg P. Hematopoietic stem cell transplantation and he-matopoietic stem cell gene therapy in X-linked adrenoleukodystrophy[J]. Brain Pathology, 2009, 20(4):857-862.
[36] Cavazzanacalvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia[J]. Nature, 2010, 467(7313):318-322.
[37] Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome[J]. Sci-ence, 2013, 341(6148):1233151.
[38] Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy[J]. Science, 2013, 341(6148):1233158.
[39] Lim W A, June C H. The principles of engineering immune cells to treat cancer[J]. Cell, 2017, 168(4):724-740.
[40] Porter D L, Levine B L, Kalos M, et al. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia[J]. New England Jour-nal of Medicine, 2011, 365(8):725-733.
[41] Brentjens R J, Davila M L, Riviere I, et al. CD19-targeted T cells rap-idly induce molecular remissions in adults with chemotherapy-refracto-ry acute lymphoblastic leukemia[J]. Science Translational Medicine, 2013, 5(177):177ra3.
[42] Swiech L, Heidenreich M, Banerjee A, et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9[J]. Nature Biotechnology, 2015, 33(1):102-106.
[43] Ran F A, Cong L, Yan W X, et al. In vivo genome editing using Staph-ylococcus aureus Cas9[J]. Nature, 2015, 520(7546):186-191.
[44] Platt R, Chen S, Zhou Y, et al. CRISPR-Cas9 knockin mice for ge-nome editing and cancer modeling[J]. Cell, 2014, 159(2):440-455.
[45] 周勇, 周一平, 简丽梅, 等. 郴州市尘肺现患病人的生命质量及其心理状况调查与分析[J]. 医药卫生, 2015(7):165-166. Zhou Yong, Zhou Yiping, Jian Hongmei, et al. The Quality of life (QOL) and psychological status of pneumoconiosis patients in Chen-zhou city[J]. Medical Science, 2015(7):165-166.
[46] More than 560 medicines in development for rare diseases[EB/OL].[2017-06-20]. http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-report-rare-diseases.pdf.
[47] Boycott K M, Vanstone M R, Bulman D E, et al. Rare-disease genet-ics in the era of next-generation sequencing:discovery to translation[J]. Nature Reviews Genetics, 2013, 14(10):681-691.
